1	Comparative evaluation of the metabolic effects of hydroxytyrosol and its
2	lipophilic derivatives (hydroxytyrosyl acetate and ethyl hydroxytyrosyl
3	ether) in hypercholesterolemic rats
4	
5	María Tabernero [§] , Beatriz Sarriá ^{∞} , Carlota Largo [§] , Sara Martínez-López ^{∞} , Andrés Madrona [‡] ,
6	José Luis Espartero [‡] , Laura Bravo ^{∞} , Raquel Mateos ^{∞} *.
7	
8	[§] Hospital La Paz Health Research Institute (IdiPaz); Madrid, Spain. [∞] Instituto de Ciencia y
9	Tecnología de Alimentos y Nutrición (ICTAN-CSIC), Madrid, Spain. [‡] Dpto. Química Orgánica y
10	Farmacéutica. Facultad de Farmacia, Universidad de Sevilla, Seville, Spain.
11	
12	
13	Running title: Metabolic effects of hydroxytyrosol and its lipophilic derivatives
14	* Corresponding author: Raquel Mateos. Department of Metabolism and Nutrition,
15	Instituto de Ciencia y Tecnología de Alimentos y Nutrición (ICTAN-CSIC). José Antonio
16	Novais 10, Ciudad Universitaria, 28040, Madrid, Spain. Phone: +34.91.544.56.07; Fax:
17	+34.91.549.36.27; e-mail: raquel.mateos@ictan.csic.es

19

20 Abstract

21 Hydroxytyrosol (HT), a virgin olive oil phenolic phytochemical with proven health benefits, has been used to generate new lipophilic antioxidants to preserve fats and oils against 22 autoxidation. The aim of this work is to comparatively evaluate the physiological effects of 23 24 HT and the lipophilic derivatives, hydroxytyrosyl acetate (HT-Ac) and ethyl hydroxytyrosyl ether (HT-Et) in a high-cholesterol fed animals. Male Wistar rats (n=8) were fed a standard 25 26 diet (C group), a cholesterol-rich diet (Chol group) or cholesterol-rich diets supplemented 27 with the phenolic compounds (HT group, HT-Ac group and HT-Et group) for 8 weeks. Body and tissue weights, lipid profile, redox status, and biochemical, hormonal, and inflammatory 28 biomarkers were evaluated. Plasma levels of total, LDL-cholesterol, glucose, insulin and 29 30 leptin, as well as malondialdehyde in serum increased in *Chol* compared to C (p<0.05). Rats 31 fed the test diets improved their glucose, insulin, leptin and MDA levels and antioxidant capacity status, being HT-Ac the most effective compound. The studied phenolic compounds 32 also modulated TNF-a and IL-1B plasma levels compared to Chol. HT-Ac and HT-Et 33 improved adipose tissue distribution and adipokine production, decreasing MCP-1 and IL-1 β 34 35 levels. Our results confirm the metabolic effects of HT, which are maintained and even improved by the hydrophobic derivatives, particularly in HT-Ac. 36

37

38 Keywords: Ethyl hydroxytyrosyl ether; hydroxytyrosol; hydroxytyrosyl acetate;
39 hypercholesterolemic rats; metabolic stress.

41 1. Introduction

The most representative phenolic compound in virgin olive oil, hydroxytyrosol 42 (HT), plays and important role in the prevention of degenerative diseases¹⁻². Explicitly, it 43 is involved in the reduction of LDL oxidation, a well-known cardiovascular risk factor³. 44 and it is transiently associates with LDL lipoproteins⁴. Moreover, HT is involved in the 45 inhibition of lipid and protein oxidation in human plasma⁵, having anti-inflammatory⁶ 46 and antiplatelet aggregation activities⁷. Additionally, there is evidence that olive oil 47 phenolic compounds decrease plasma glucose levels in rats⁸⁻⁹. HT can be efficiently 48 49 recovered from olive by-products, which has prompted the study of the biological and health effects of HT from alperujo^{8, 10} or olive leaves.^{9, 11} 50

On the other hand, the food industry demands new lipophilic antioxidants to 51 preserve fats and oils against autoxidation. Two series of hydrophobic derivatives of HT, 52 hydroxytyrosyl esters¹² and hydroxytyrosyl ethers¹³, have been synthesized. 53 Hydroxytyrosyl acetate (HT-Ac) merits special interest among hydroxytyrosyl esters, 54 since it is an antioxidant naturally present in virgin olive oil¹⁴ that is transported across 55 the small intestinal epithelial cell barrier more efficiently than HT,¹⁵ showing a higher 56 hepatic bioavailability than HT¹⁶. Moreover, HT-Ac has shown protective effects against 57 oxidative DNA damage in blood cells¹⁷, iron-induced oxidative stress in human cervical 58 cells,¹⁸ and oxidative stress in HepG2 cells¹⁹. Hydroxytyrosyl ethyl ether (HT-Et), with an 59 alkyl chain with the same length as the acyl chain in HT-Ac, was included in this study to 60 assess the influence of the different functional groups (etherification versus esterification) 61 62 on the biological activity of the two phenolic compounds. HT-Et is absorbed to a higher 63 extent in Caco-2 cells than its precursor HT,²⁰ with absorption rate similar to that of HT-64 Ac,¹⁵ being also broadly taken-up by HepG2 cells²¹. In addition, HT-Et protects hepatic 65 human HepG2 cells against oxidative stress²² and inhibits platelet activation after oral

administration in rats²³. These antecedents justify using this compound although it is not
naturally present in virgin olive oil.

68 Both HT-Ac and HT-Et maintain the orthodiphenolic group intact and show 69 higher antioxidant capacity than HT²⁴⁻²⁵, preserving their potential application as 70 antioxidants to stabilize foodstuffs or as functional food ingredients.

With these antecedents, the aim of the present study was to comparatively analyse the ability of HT and its lipophilic derivatives, HT-Ac and HT-Et, counteracting the metabolic deregulation derived from consuming a high-cholesterol diet, focusing on the effects on plasma lipids, glucose levels, hormone response, oxidative stress and proinflammatory status. In addition, body weight gain, adipose tissue distribution and secretion of adipokines from visceral fat were evaluated.

77

78 2. Experimental

79 2.1. Materials and Chemical

80 Cholesterol, cholic acid, palmitic acid, 6-hydroxy-2,5,7,8-tetramethylchroman-2-81 carboxilic acid (Trolox), 1,1,3,3-tetraethoxypropane, fluorescein, 2,2'-azobis(2amidinopropane) dihydrochloride 82 (AAPH), trizmabase, dithiothreitol, 1,1,3,3tetraethoxypropane and 2.4-dinitrophenylhydrazine were purchased from Sigma-Aldrich 83 Chemical (Madrid, Spain). Sodium hydroxide, sulphuric acid, sodium hydrogen phosphate 84 and potassium dihydrogen phosphate were from Panreac (Madrid, Spain). The Bradford 85 reagent was from BioRad (BioRad Laboratories S.A., Madrid, Spain). Free fatty acids (FFA) 86 colorimetric kit was purchased from Roche (Roche Applied Science, Madrid Spain). Rat 87 88 adipocyte (RADPCYT-82K, MilliplexMap Rat Adipocyte Panel) and adipokine (RADPK-81K, MilliplexMap Kit Rat Serum Adipokine Panel) Milliplex kits were acquired from 89

90 Millipore (Millipore, Billerica, MA, US, USA). Other reagents were of analytical or 91 chromatographic quality.

HT was isolated with 98% purity from olive oil waste water following a patented
 procedure ²⁶ and further purified by column chromatography.

94 HT-Ac was obtained from HT in ethyl acetate after incubation with p-95 toluenesulfonic acid and purification by column chromatography following a patented 96 procedure ¹².

97 HT-Et was obtained from HT by chemical synthesis as described elsewhere 13 .

98

99 2.2. Diet, animals and experimental design

Forty male Wistar rats (200–225 g body weight) were purchased from an accredited 100 101 supplier (Charles River Laboratorios España, S.A. Barcelona, Spain) and housed in 102 metabolic cages. They had free access to food and water, and were maintained under a 103 normal light-dark cycle in the Experimental Surgery Service of La Paz University Hospital 104 (registration number: 280790001941). After one week of acclimation, animals were 105 randomly distributed into 5 different experimental groups (8 rats per group). One group 106 received the standard, maintenance rodent diet (A04-SAFE, Augy, France), which is the 107 control (C group), and four groups were fed the standard diet supplemented with 2% 108 cholesterol and 0.4% cholic acid in order to generate the hypercholesterolemic model as 109 described elsewhere ²⁷. In three of these groups the hypercholesterolemic diet was 110 supplemented with 0.04% of HT (HT group), HT-Ac (HT-Ac group) and HT-Et (HT-Et 111 group), respectively, to assess the potential beneficial effects of these phenolic compounds in 112 the hypercholesterolemic rat model. Nutritional and energetic content of each diet is 113 summarized in Table 1. During the whole intervention, animal health status and dietary 114 tolerance were monitored by veterinary individual observation in addition to weekly control

115 of animals' weight (Table 2). After 8 weeks animals were subjected to complete 116 exsanguination under general anesthesia (isoflurane 2%). Plasma and serum fractions were 117 separated by centrifugation (10 minutes at 2500 g) using pretreated EDTA or Silica Act Cot 118 Activator blood collection tubes (BD Vacutainer, Plymouth, UK) respectively, and stored at -119 20°C until further analysis. Liver, kidney, heart and adipose tissue from retroperitoneal and 120 epididymal areas were collected, weighed and washed in ice-cold phosphate buffered saline. 121 Samples were immediately frozen in liquid nitrogen and stored at -80°C until analysis. The 122 study protocol was approved by the Institutional Animal Ethics Committee of La Paz 123 University Hospital (Madrid, Spain) and procedures were performed in accordance with 124 Spanish law for the protection of experimental animals and other research purposes (RD 125 53/2013, BOE n° 34 Sec I pg 11370 8th February 2013).

126

127 2.3. Blood biochemical analyses

Triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, glucose and creatinine in plasma were determined using an automated analyser (Beckman Coulter-Former Olympus Diagnostics AU 5420, Nyon, Switzerland). Plasma free fatty acids (FFA) concentration was determined with a colorimetric commercial assay kit (Free Fatty Acids, Half Micro Test, Roche Applied Science) using palmitic acid as standard.

133

134 2.4. Determination of oxygen radical scavenging capacity (ORAC) in serum.

Serum antioxidant activity was analysed using the hydrophilic oxygen radical scavenging capacity (ORAC) assay according to the method developed by Huang, Ou, Hampsch-Woodill, Flanagan& Prior²⁸. The fluorescence at 485 and 528nm excitation and emission wavelengths, respectively, was determined in a 96 well microplate reader (Bio-Tek, Winooski, VT, USA). ORAC values were expressed as micromoles of Trolox / mL serum.

140

141 2.5. Determination of Malondialdehyde (MDA) in serum and liver.

MDA was determined as its hydrazone by high-performance liquid chromatography using 2,4-dinitrophenylhydrazine for derivatization²⁹. Livers (0.5g) were homogenized (1:5 w/v) in ice-cold 0.25M Trizma base buffer pH 7.4 containing 5mM dithiothreitol using an Ultra Turrax (IKA® Works Inc., WilmingtonNC) at 18000 rpm. After centrifugation (11000rpm 30min, 4°C), supernatants were collected for MDA quantification. Serum samples were analysed directly. Standard MDA was prepared by acidic hydrolysis of 1,1,3,3tetraethoxypropane in 1% sulphuric acid. Concentrations were expressed as nanomoles of MDA per milligram of protein in liver tissue and per millilitre in serum. Protein content in liver homogenates was estimated by the Bradford method using a Bio-Rad protein assay kit.

151

152 2.6. Determination of cytokines and hormones in plasma and adipose tissue by 153 immunoassay.

A sample of white adipose tissue from the retroperitoneal area (0.2g) was collected and homogenized (1:3.5 w/v) in PBS (pH 7.4) with Triton X-100 and protease inhibitor by low temperature sonication (17 microns, 3 consecutive pulses of 15 seconds at 30 seconds intervals). After centrifugation (5000rpm, 10min, 4°C), the lipid layer was removed and supernatants were collected for adipokine determination. The concentration of leptin, interleukin-1 β (IL-1 β), interleukin-6 (IL-6), tumour necrosis factor- α (TNF- α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in the retroperitoneal adipose tissue were determined using a Rat Adipocyte Multiplex Kits (RADPCYT-82K Milliplex Map Kit, Rat Adipocyte Panel, Millipore, Billerica, MA, US). IL-1 β , IL-6, TNF- α , insulin and leptin concentrations were determined in plasma samples obtained at the end of the intervention using a Rat Adipokine multiplex kits (RADPK-81K,

Milliplex Map Kit, Rat Serum Adipokine Panel, Millipore, Billerica, MA, US). Multianalyte profiling panels were used according to manufacturer's instructions and analysed on a LuminexLX200 Analyzer. Data were analysed using the 3.1 xPONENT software (Millipore); high and low concentration quality controls were used with all the biomarkers. Protein content in adipose tissue homogenates was estimated by the Bradford method using a Bio-Rad protein assay kit.

171

172 2.7. Statistical analysis.

173 All data were expressed as the mean \pm standard deviation (SD). Non parametric 174 significant test (Kruskal-Wallis one-way analysis of variance and Mann-Whitney *U* test) was 175 performed to compare values. Differences were considered statistically significant when p < 176 0.05 and in Mann-Whitney *U* test the significance was adjusted with a Bonferroni test. Data 177 were analysed using the statistical package SPSSv.19.0 software (SPSS, Institute Inc, Cary, 178 NC).

179

180 **3. Results**

181 3.1.Food intake, body weight gain and tissues weights

All diets provided equivalent amounts of carbohydrates and proteins. However, cholesterol-rich diets led to an excess of lipids resulting in an 8.5 Kcal/100g higher caloric intake. During the 8-week study period, animals in the five experimental groups had similar daily food intakes (approximately 20g/d).

Therefore, the groups consuming the cholesterol-rich diets (*Chol*, *HT*, *HT-Ac* and *HT-Et*) presented a daily caloric excess of approximately 2 Kcal/day. However, this did not induce significant differences in the body weight gain compared with the control animals, as can be seen in Table 2.

Considering an average daily food intake of 20g and an average body weight of 300g, the daily phenolic compound intake was 25 mg/kg body weight/day. This is a relatively low dose, comparable with doses used in some other studies ⁸⁻¹¹ and within a range proven to elicit no toxic effects in rats. Accordingly, no pathologic alterations or behaviours were observed in the animals during the study. Organs, including kidney or heart among others, presented normal appearance by gross observation. However, livers in animals fed the cholesterol-rich diets showed a whitish appearance compared with the *C* group, suggestive of fat accumulation, being significantly heavier than those of the *C* group (Table 2). Adipose tissue depots were obtained from retroperitoneal and epididymal areas, and when their weights were normalized for the final animal body weight, no differences were observed among different treatments. However, the ratio obtained with the adipose tissue from retroperitoneal area/epididymal area showed significant differences, being higher in the *Chol* and *HT* groups than in the *C* group.

203

204 3.2. Plasma cholesterol profile

As Figure 1 shows, animals fed the cholesterol-rich diets had a marked hyperlipidaemia, with high LDL-cholesterol and total cholesterol concentrations, although HDL-cholesterol levels were not affected as compared to *C* group. Although not reaching the values of control animals, supplementation of the cholesterol-rich diet with 0.04% HT-Ac significantly decreased the total cholesterol and LDL-cholesterol levels as compared with the *Chol* group (p<0.05), which was not attained in the *HT* and *HT-Et* groups.

211

212 3.3. Biochemical parameters and hormones involved in energy homeostasis

The high-cholesterol diet used in the present study induced a significant increase in glucose levels in the *Chol* group compared to control animals (p<0.05). All the tested

215 phenolic compounds counteracted the glucose increase, with a partial effect of HT-Et 216 whereas values in *HT-Ac* and *HT* groups returned to control levels (Table 3).

Triglycerides concentrations were similar in all groups, although phenolic compounds supplementation induced a moderate yet non-significant decrease. No differences were observed in plasma concentrations of free fatty acids, whereas creatinine concentrations were statistically higher in *Chol* and *HT* groups, compared to *C*, *HT-Ac* and *HT-Et* groups (Table 3).

After consuming the high-cholesterol diet for 8 weeks significant differences in plasma insulin and leptin concentrations were observed in *Chol* compared to *C* group. However, rats consuming diets supplemented with HT and HT-Ac had significantly lower plasma insulin levels than *Chol*, decreasing to control or even lower values as in the HT-Ac group (Table 3). *HT-Et* also presented lower insulin levels than *Chol* group although not statistically different (p=0.070), showing intermediate values between *Chol* and *C* groups. Leptin levels were lower in *HT* and *HT-Et* groups than in the *Chol* group, although not reaching values of control animals. Again, *HT-Ac* group had significantly lower plasma leptin levels than *Chol* group and in the range of the control values. In the retroperitoneal adipose tissue, leptin concentration was slightly lower in all cholesterol treated groups compared to the *C* animals, although not significantly different.

233

234 **3.4.** Redox status and inflammatory biomarkers in blood and tissue samples

Serum antioxidant activity (Table 4), analysed using the ORAC assay, was lower in Chol group compared to the control group without reaching the level of statistical significance. However, rats fed with HT and HT-Ac diets showed a significantly higher serum antioxidant activity compared with Chol group (p<0.05).

Regarding the biomarker of lipid peroxidation, *Chol* group showed MDA levels significantly higher than *C* animals in serum and liver (p<0.05). Supplementation with any of the studied phenolic compounds decreased MDA levels to control values in serum (Table 4). However, although the three phenolic compounds-supplemented groups showed lower hepatic MDA levels than *Chol* group, differences were statistically significant only in the *HT-Et* group (p<0.05) (Table 4).

245 Consuming the cholesterol-rich diet significantly increased the pro-inflammatory 246 cytokine TNF α plasma concentrations compared to *C* group, effect that was totally 247 counteracted by the three phenolic compounds (Table 4). A similar response was observed 248 with IL-1 β , with increased values in the *Chol* group returning to control levels in the *HT*, *HT*-249 *Ac* and *HT-Et* animals, although differences did not reach the level of statistical significance 250 (Table 4). Plasma IL-6 was not affected by the cholesterol-rich diets or the phenolic 251 supplementation.

252 Cytokine concentrations in the visceral adipose tissue from retroperitoneal area of the 253 rats in the *Chol* group were similar to those in *C* group. TNF α and IL-6 concentrations were 254 unchanged in all the experimental groups; however, IL-1 β concentrations were lower in *HT*-255 *Ac* and *HT-Et* groups. Accordingly, MCP-1 showed significantly lower concentrations in 256 *HT-Ac* and *HT-Et* groups compared to *C* group (Table 4). PAI-1 concentrations showed 257 similar tendency, but differences did not reach statistical significance.

258

259 4. Discussion

In the present study the effects of HT were studied in comparison with HT-Ac and HT-Et, two lipophilic derivatives of HT with a higher intestinal bioavailability than their precursor^{15, 20}. The evaluation of the biological properties of these three compounds was performed focusing on plasma lipids, energy homeostasis and oxidative and inflammatory

status in rats fed a cholesterol-rich diet. This study shows that HT and its hydrophobic derivatives induce beneficial metabolic effects in hypercholesterolemic rats. Particularly, HT-Ac showed the highest capacity to counteract the metabolic stress induced by the highcholesterol diet.

Supplementation of the diets with a moderate amount of phenolic compounds (0.04%) resulted in a daily intake of 25mg/kg body weight, which is far beyond any possible toxic level considering a recently published a study where consumption of up to 500 mg/kg/day was described as a No Observed Adverse Effects Level (NOAEL)³⁰.

As expected, feeding rats with a diet rich in cholesterol resulted in an increase in total cholesterol and LDL cholesterol levels. In this hypercholesterolemic model, HT and HT-Et showed modest plasma LDL-cholesterol lowering effects, in contrast to HT-Ac that significantly reduced total and LDL-cholesterol levels compared to *Chol* group. These results are in line with previous human and animal studies showing that phenolic compounds present in virgin olive oil exert beneficial cardiovascular effects, particularly improving lipid profile⁸, ^{10, 31}. In fact, the European Food Safety Authority has recently issued a positive opinion on olive oil phenolic compounds capacity to protect LDL cholesterol from oxidative damage³².

Several markers show that rats in the present study suffered hepatic stress induced 280 by the cholesterol-rich diet, which may have led to an incipient insulin resistance². 281 282 Comparing the *Chol* and *C* groups, the high-cholesterol diet induced a significant increase in 283 glucose, creatinine, insulin and leptin plasma concentrations. In addition, Chol 284 hypercholesterolemic animals presented higher liver weights than C animals and the adipose depots were mainly distributed in the retroperitoneal area. Interestingly, the diets 285 supplemented with phenolic compounds counteracted the glucose and insulin increase, 286 287 particularly HT and HT-Ac. This outcome is in accordance with previous studies showing 288 that HT and other olive oil phenolic compounds reduce plasma glucose concentration in

289 alloxan-diabetic rats⁸⁻⁹ by means of alleviating oxidative stress and free radicals as well as 290 enhancing enzymatic defences. A recent paper evidenced the capacity of oleuropein aglycone in the prevention of cytotoxic amyloid aggregation of human amylin, a hallmark of Type-II 291 diabetes³³. In accordance, the PREDIMED study showed that consuming a virgin olive oil-292 293 enriched traditional Mediterranean diet for three months decreased total and LDL cholesterol 294 together with plasma glucose in asymptomatic high cardiovascular-risk patients, although no changes were observed in insulin levels³⁴. In line with these results, a significant decrease of 295 glycaemia related to a long term daily intake of a virgin olive oil rich in phenolic compounds 296 297 was observed in healthy young subjects³⁵. HT-Ac also maintained plasma leptin at concentrations similar to those in the C group, while this effect was more discrete in the case 298 299 of HT and HT-Et. Similarly, in rats that consumed the diet supplemented with HT-Ac and 300 HT-Et creatinine concentrations were restored to control levels, but not with HT. The renal 301 protective effect of olive phenols reducing creatinine levels has already been described in 302 diabetic rats⁸.

303 The retroperitoneal/epididymal fat ratio provides information about adipose tissue distribution, being directly proportional to the abdominal fat accumulation. Both 304 retroperitoneal and epididymal adipose depots are considered visceral fat associated with 305 306 higher levels of inflammation and lipolysis than subcutaneous fat, having been related with insulin resistance³⁶. The retroperitoneal adipose depots in rats could be related to abdominal 307 308 adiposity in humans since they are located inside the peritoneum attached to the dorsal area 309 of the abdomen, whereas epididymal adipose tissue would correspond to gonadal fat, which 310 exists in mice and rats but not in humans. The groups supplemented with the lipophilic 311 compounds (HT-Ac and HT-Et) moderately improved the retroperitoneal/epididymal fat ratio 312 compared to *Chol* group, whereas the group that consumed HT did not show changes. Our 313 results are in agreement with the reduction in abdominal fat deposition described in a

314 metabolic syndrome animal model that consumed a diet supplemented with an olive leaf 315 extract rich in HT³⁷.

Metabolic disturbance which includes hyperlipidaemia, hyperglycaemia and 316 317 hyperinsulinemia often involves chronic inflammation and oxidative stress^{2, 8, 11}. Therefore, 318 redox status and inflammatory biomarkers were analyzed in plasma in order to understand 319 the potential mechanisms underlying the effects of the studied phenolic compounds. 320 Although the possible health implications related to MDA changes remain unknown, in this 321 study elevated systemic MDA concentrations were observed in the *Chol* group, suggesting a 322 marked oxidative stress in these animals that was counteracted by the consumption of the 323 phenolic compounds. Moreover, the serum antioxidant capacity of animals consuming the 324 phenolic compounds was higher than in the *Chol* group, particularly HT and HT-Ac. 325 However, at the hepatic level phenolic compounds supplementation did not decrease MDA 326 levels to control values although hepatic peroxidation was reduced in all cases, especially in 327 the *HT-Et* group (Table 4). It is noteworthy that the studied phenolic compounds follow 328 different metabolic pathways when ingested.HT-Ac is extensively hydrolysed into free HT, 329 whereas HT-Et remains unaltered, yielding more lipophilic metabolites than those generated 330 after HT and HT-Ac hepatic metabolism^{15, 20}. This would result in higher HT-Et 331 bioaccumulation in hepatic tissue, conferring higher protection against oxidation than HT and 332 HT-Ac metabolites.

The protective role of olive oil phenolic compounds against oxidative damage is well established and has been reviewed recently¹. The antioxidant and free radical scavenging capacity of olive oil phenols seem to be related to their anti-inflammatory effects, which have been reported in different animal models^{38, 39}. Gong, Geng, Jiang, Cao, Yoshimura&Zhong⁴⁰ showed the capacity of HT to decrease the pro-inflammatory cytokines IL-1 β and TNF α but not to increase the anti-inflammatory cytokine IL-10 in carrageenan-

induced acute inflammation and hyperalgesia in rats. Moreover, the role of olive oil phenols reducing postprandial inflammatory response in obese subjects has been recently attributed to the inhibition of NF- κ B, which is an important link between oxidation and inflammation in the postprandial state⁴¹. In the present study, diets supplemented with HT, HT-Ac and HT-Et had anti-inflammatory effects decreasing plasma TNF α in rats fed cholesterol-rich diet. Similar behaviour was observed with IL-1 β although not reaching statistical significance probably due to the high variability that this parameter presented in the *Chol* group. In adipose tissue, supplementation with HT-Ac and HT-Et decreased MCP-1 and IL-1 β below control levels.

Nutrients' mechanisms of action are strongly related with the capacity to modulate 348 gene expression. Llorente-Cortes and co-workers³⁴ showed that consuming a traditional 349 350 Mediterranean diet enriched with virgin olive oil for three months improved lipid profile and 351 plasma glucose levels, prevented the increased expression of cyclooxigenase-2 (COX2) and 352 LDL receptor-related protein-1 (LRP-1) genes, and reduced the expression of MCP1 gene 353 compared with a traditional Mediterranean diet enriched with nuts or with a low fat diet. 354 COX2 and MCP1 genes are involved in inflammation whereas LRP1 takes part in foam cell 355 formation. Likewise, Konstantinidou and co-workers³¹ observed lower plasma oxidative and 356 inflammatory status in healthy subjects after consuming for three months a Mediterranean 357 diet supplemented with virgin olive oil rich in phenolic compounds compared to the control 358 group. In the study, pro-atherogenic genes related with inflammation (IFN γ , ARHGAP15 and 359 IL7R) and oxidative stress (ADRB2) were down-regulated in peripheral blood mononuclear 360 cells (PBMCs). Changes in gene expression were associated with decreases in lipid oxidative 361 damage and systemic inflammation markers. In vitro studies have established the capacity of 362 HT to modulate adjocyte lipid content and gene expression partially mediated by the 363 reduction of the transcription factors PPAR α and C/EBP α^{42} . In phytochemicals' capacity to

modify gene expression in different tissues and cell lines, the chemical structure of the phytochemical plays an important role not only in their direct scavenging of free radicals, but also in the target protein and therefore in the molecular mechanism involved in its biological action. Thus, considering the extensive hydrolysis that HT-Ac undergoes during intestinal absorption yielding HT ¹⁵, both compounds could follow similar mechanisms to regulate the unbalance induced by the high-cholesterol rich diet. Our results suggest changes in the expression of redox and inflammatory related genes, based on studies recently published by other research groups; however, further work is required to elucidate the molecular mechanisms underlying the regulatory metabolic effect of HT and its derivatives.

A limitation of this study is that a control group fed a standard diet supplemented with HT was not included to assess the effect of this compound within a balanced diet in healthy animals.

In summary, HT and its lipophilic derivatives, HT-Ac and HT-Et, were able to reduce the metabolic unbalance induced by a high-cholesterol diet in rats, being HT-Ac, the lipophilic HT derivative naturally present in virgin olive oil, the most effective phenolic compound. Since HT-Ac can be easily obtained from natural HT¹², this compound might be proposed as an interesting bioactive ingredient in the production of functional foods, having the added value of contributing to induce beneficial metabolic properties.

382

List of abbreviations: C group: Control group ; **Chol group:** cholesterol-rich diet group; **AAPH:** 2,2'-azobis (2-amidinopropane) dihydrochloride; **COX 2**: cyclooxigenase-2; **FFA**: **Free fatty acids; HT:** hydroxytyrosol; **HT-Ac:** hydroxytyrosyl acetate; **HT-Et:** ethyl hydroxytyrosyl ether; **IL-1b**: interleukin-1 β ; **IL-6**: interleukin-6; **LRP1**: LDL receptorrelated protein-1; **MCP-1**: monocyte chemoattractant protein-1; **ORAC**: oxygen radical scavenging capacity; **PAI-1**: plasminogen activator inhibitor-1; **SD**: standard deviation; **TNF-a**: tumour necrosis factor- α ; **Trolox**: 6-hydroxy-2,5,7,8-tetramethylchroman-2got carboxilic acid

391

392 Acknowledgements

393 Study funded by projects RTA2007-00036 (INIA), Excellence Project AGR-5098 394 (Junta de Andalucia) and Consolider-Ingenio (CSD2007-00063). The authors thank the 395 technical support and expertise in blood analysis provided by CORE lab (University Hospital 396 La Paz).SM-L is a JAE predoctoral fellow funded by CSIC and the European Social Fund. 397

398

399 Conflict of interest statement

400 The authors have declared no conflict of interest.
401
402
403
404
405

407 References

- 408 1. M. I. Fernandez-Mar, R. Mateos, M. C. Garcia-Parrilla, B. Puertas, and E. Cantos409 Villar, *Food Chem.*, 2012, 130, 797-813.
- 410 2. A. Dey and J. Lakshmanan, *Food Funct.*, 2013, **4**, 1148-1184.
- 411 3. K. De la Torre-Carbot, J. L. Chávez-Servín, O. Jaúregui, A. I. Castellote, R. M.
- 412 Lamuela-Raventós, T. Nurmi, H. E. Poulsen, A. V. Gaddi, J. Kaikkonen, H. F.
- 413 Zunft, H. Kiesewetter, M. Fitó, M. I. Covas, and M. C. López-Sabater. J. Nutr.,
- 414 2010, **140**, 501-508.
- 415 4. M. Gonzalez-Santiago, J. Fonolla, and E. Lopez-Huertas. *Pharm. Res.*, 2010, 61,
 416 364-370.
- 417 5. J. Ruano, J. López-Miranda, F. Fuentes, J. A. Moreno, C. Bellido, P. Perez418 Martinez, A. Lozano, P. Gómez, Y. Jiménez, and F. Pérez Jiménez, J. Am. Coll.
 419 Cardiol. 2005, 46, 1864–1868.
- 420 6. P. Bogani, C. Galli, M. Villa and F. Visioli, *Atherosclerosis*. 2007, **190**, 181–186.
- 421 7. J. Ruano, J. López-Miranda, R. de la Torre, J. Delgado-Lista, J.Fernández, J.
 422 Caballero, M. I. Covas, Y. Jiménez, P. Pérez-Martínez, C. Marín, F. Fuentes and F.
 423 Pérez-Jiménez. *Am. J. Clin. Nutr.* 2007, **86**, 341–346.
- 424 8. K. Hamden, N. Allouche, M.Damak, and A. Elfeki, *Chem. Biol. Interact.*, 2009,
 425 180, 421–432.
- 426 9. H. Jemai, A. E. Feki, and S. Sayadi, J. Agric. Food Chem. 2009, 57, 8798–8804.
- 427 10. G. Rodriguez-Gutierrez, G.G. Duthie, S. Wood, P. Morrice, F. Nicol, M. Reid, L.L.
- 428 Cantlay, T. Kelder, G.W. Horgan, J.F.B. Guzman, and B. de Roos, B. Mol. Nutr.
- 429 Food Res. 2012, **56**, 1131-1147.
- 430 11. H. Jemai, I. Fki, M. Bouaziz, Z. Bouallagui, A.E. Feki, H. Isoda, and S.Sayadi, J.
- 431 *Agric. Food Chem.* 2008, **56**, 2630–2636.
- 432 12. F. Alcudia, A. Cert, J.L. Espartero, R. Mateos, and M. Trujillo, PCT
 433 WO2004/005237. (2004).

- 434 13. A. Madrona, G. Pereira-Caro, R. Mateos, G. Rodriguez, M. Trujillo, J. Fernandez-
- 435 Bolanos, and JL.Espartero, *Molecule*, 2009, **14**, 1762–1772.
- 436 14. R. Mateos, J.L. Espartero, M. Trujillo, JJ. Ríos, M. León-Camacho, F. Alcudia, A.
- 437 Cert, J. Agric. Food Chem. 2001, **49**, 2185–2192.
- 438 15. R. Mateos, G. Pereira-Caro, S. Saha, R. Cert, M. Redondo-Horcajo, L. Bravo and
- 439 P.A. Kroon, *Food Chem.* 2011, **125**, 865–872.
- 440 16. R. Mateos, L. Goya, and L.Bravo, J. Agric. Food Chem. 2005, 53, 9897–9905.
- 441 17. S. Grasso, L. Siracusa, C. Spatafora, M. Renis and C. Tringali, *Bioorg. Chem.* 2007,
- **35**, 137–152.
- 18. Z. Bouallagui, M. Bouaziz, S. Lassoued, J.M. Engasser, M. Ghoul and S. Sayadi, *Appl. Biochem. Biotechnol.* 2011, 163, 592-599.
- 445 19. G. Pereira-Caro, R. Mateos, B. Sarria, R. Cert, L. Goya and L. Bravo, *Food Chem.*446 2012, **131**, 869–878.
- 20. G. Pereira-Caro, R. Mateos, S. Saha, A. Madrona, J.L. Espartero, L. Bravo, L. and
 P.A. Kroon, J. Agric. Food Chem. 2010, 58, 11501–11509.
- 449 21. G. Pereira-Caro, L. Bravo, A. Madrona, J.L. Espartero and R. Mateos, J. Agric.
 450 Food Chem. 2010, 58, 798–806.
- 451 22. G. Pereira-Caro, B. Sarria, A. Madrona, J.L. Espartero, L. Goya, L. Bravo and R.
- 452 Mateos, J. Agric. Food Chem. 2011, **59**, 5964–5976.
- 453 23. J. Munoz-Marin, J.P. De La Cruz, J.J. Reyes, J.A Lopez-Villodres, A. Guerrero, I.
- Lopez-Leiva, J.L. Espartero, M.T. Labajos, and J.A. Gonzalez-Correa, *Food Chem. Toxicol.*, 2013, **58**, 295-300.
- 456 24. G. Pereira-Caro, A. Madrona, L. Bravo, J.L. Espartero, F. Alcudia, A. Cert, and R.
- 457 Mateos, *Food Chem.* 2009,**115**, 86–91.
- 458 25. R. Mateos, M. Trujillo, G. Pereira-Caro, A. Madrona, A. Cert, and J.L. Espartero, J.
- 459 Agric. Food Chem. 2008, **56**, 10960–10966.

- 460 26. J. Fernandez-Bolaños, A. Heredia, G. Rodríguez, R. Rodríguez, A. Jiménez and R.
- 461 Guillen, US 6,849,770 B2. 2005.
- 462 27. S.G. Sayago-Ayerdi, R. Mateos, R.I. Ortiz-Basurto, C. Largo, J. Serrano, A.B.
- 463 Granado-Serrano, B. Sarria, L. Bravo, M. Tabernero, *Food Chem.* 2014, **148**, 54-59.
- 464 28. D. Huang, B. Ou, M. Hampsch-Woodill, J.A. Flanagan and R.L. Prior, J. Agric.
- 465 *Food Chem.* 2002, **50**, 4437-4444.
- 466 29. R. Mateos, E. Lecumberri, S. Ramos, L. Goya and L. Bravo, J. Chromatogr. B.
 467 Analyt. Technol. Biomed. Life Sci. 2005, 827, 76–82.
- 468 30. D. Aunon-Calles, L. Canut, F. Visioli, Food Chem. Toxicol. 2013, 55, 498-504.
- 469 31. V. Konstantinidou, M.I. Covas, D. Munoz-Aguayo, O. Khymenets, R. De la Torre,
- G. Saez, M.C. Tormos, E. Toledo, A. Marti, V. Ruiz-Gutiérrez, M.V. Ruiz-Mendez
 and M. Fitó, *Faseb. J.* 2010, 24, 2546-2557.
- 472 32. EFSA Panel on Dietetic Products, Nutrition and Allergies, *EFSA Journal*, 2011, 9,
 473 2033-2058.
- 474 33. S. Rigacci, V. Guidotti, M. Bucciantini, M. Parri, C. Nediani, E. Cerbai, M. Stefani,

475 and A. Berti, J. Nutr. Biochem. 2010, **21**, 726-735.

- 476 34. V. Llorente-Cortes, R. Estruch, M.P. Mena, E. Ros, M.A. González, M. Fitó, R.M.
- 477 Lamuela-Raventós, and L. Badimon, *Atherosclerosis* 2010, **208**, 442–450.
- 478 35. M.J. Oliveras-Lopez, M. Innocenti, F. Martín-Bermudo, H. Lopez-Garcia de la
 479 Serrana and N. Mulinacci, *Eur. J. LipidSci. Technol.* 2012, **114**, 999-1006.
- 36. S. Yamashita, T. Nakamura, I. Shimomura, M. Nishida, S. Yoshida, K. Kotani, K.
 Kameda-Takemuara, K. Tokunaga and Y. Matsuzawa, *Diabetes Care*, 1996, 19, 287-291.
- 483 37. H. Poudyal, F. Campbell and L. Brown, J. Nutr. 2010, 140, 946-953.
- 484 38. R. De la Puerta, E. Martínez-Domínguez and V Ruíz-Gutiérrez, Z Naturforsch C.
- 485 2000, **55**, 814–819.

486	39. C. Puel, J. Mardon, A. Agalias, M.J. Davicco, P. Lebecque, A. Mazur, M.N.
487	Horcajada, A.L. Skaltsounis and V. Coxam, J Agric Food Chem. 2008, 56, 9417-
488	9422.
489	40. D. Gong, C. Geng, L. Jiang, J. Cao, H. Yoshimura, and L.E. Phytother. Res. 2009,
490	23 , 646–650.
491	41. A. Perez-Herrera, J. Delgado-Lista, L.A. Torres-Sanchez, O.A., Rangel-Zuñiga, A.
492	Camargo, J.M. Moreno-Navarrete, B. Garcia-Olid, G.M. Quintana-Navarro, J.F.
493	Alcala-Diaz, C. Muñoz-Lopez, F. Lopez-Segura, J.M. Fernandez-Real, M.D. Luque
494	de Castro, J. Lopez-Miranda and F. Perez-Jimenez, Mol. Nutr. Food Res. 2012, 56,
495	510-514.
496	42. I. Warnke, R. Goralczyk, E. Fuhrer and J. Schwager, Nutr. Metab. 2011, 8, 1-13.
497	
498	
499	
500	
501	
502	
503	
504	
505	
506	
507	
508	

509

510 Figure Legends


511

512	Figure 1. Plasma lipid profile (total-cholesterol, LDL- and HDL-Chol) of rats fed for 8
513	weeks with standard diet (C group), cholesterol-rich diet (Chol group) and cholesterol-rich
514	diet supplemented with hydroxytyrosol (HT group), hydroxytyrosyl acetate (HT-Ac) and

- 515 ethyl hydroxytyrosyl ether (HT-Et). Data represent the means of 8 determination \pm SD. Bars
- 516 without a common letter differ, p < 0.05.

517

Figure 1.



Component (g/100g dry weight)	С	Chol	HT	HT-Ac	HT-Et
Carbohydrates	65.93	64.20	64.17	64.17	64.17
Protein	17.58	17.12	17.11	17.11	17.11
Lipids (others than cholesterol)	3.30	3.21	3.21	3.21	3.21
Cholesterol	0.00	2.19	2.19	2.19	2.19
Cholic acid	0.00	0.44	0.44	0.44	0.44
HT and derivatives	0.00	0.00	0.04	0.04	0.04
Caloric content (Kcal/100g)	219.2	227.7	227.7	227.7	227.7

 Table 1. Dietary composition of the experimental diets.

1 Table 2. Body and tissue weights of rats in the control group (C), the group consuming the non-supplemented cholesterol-rich diet (Chol) or the

2 cholesterol-rich diet supplemented with hydroxytyrosol (HT), hydroxytyrosyl acetate (HT-Ac) and ethyl hydroxytyrosyl ether (HT-Et). Data

3 represents the mean of 8 determinations \pm SD*.

	Standard diet		Hypercholesterolemic diet			
	С	Chol	HT	HT-Ac	HT-Et	
Body weight (g)						
Inicial	242 + 6	244 + 8	244 + 7	239 + 11	243 + 4	
Final	336 + 18	326 + 30	331 + 16	317 + 10	329 + 14	
Body weight gain (g/56d)	94 + 15	82 + 32	87 + 12	78 + 11	86 + 12	
Tissue weights (g)						
Epididymal fat/ body weight	0.016 + 0.003	0.016 + 0.002	0.015 + 0.001	0.017 + 0.003	0.015 + 0.004	
Retroperitoneal fat/ body weight	0.018 + 0.004	0.015 + 0.002	0.014 + 0.002	0.017 + 0.001	0.016 + 0.005	
Ratio Retroperitoneal/epididymal	0.88 ± 0.09^{a}	1.07 ± 0.08^{b}	1.07 ± 0.08^{b}	$1.00 + 0.05^{ab}$	0.93 ± 0.07^{ab}	
Liver / body weight	0.024 ± 0.002^{a}	0.038 ± 0.003^{b}	0.029 ± 0.018^{ab}	$0.036 + 0.002^{b}$	0.037 ± 0.002^{b}	
Kidney / body weight	0.0053 + 0.0022	0.0057 ± 0.0005	0.0058 ± 0.0008	0.0061+0.0005	0.0059 + 0.0006	
Heart / body weight	0.0026 + 0.0003	0.0028 + 0.0005	0.0025 + 0.0001	0.0029 + 0.0005	0.0028 + 0.0003	

4 * Mean values in a row with unlike superscripts are significantly different according to Kruskal-Wallis one-way analysis of variance and Mann-Whitney

5 U test (p < 0.05).

6

8 **Table 3.** Metabolic biomarkers in plasma and adipose tissue of rats in the control group (*C*), the group consuming the un-supplemented 9 cholesterol-rich diet (*Chol*) or the group fed the cholesterol-rich diet supplemented with hydroxytyrosol (*HT*), hydroxytyrosyl acetate (*HT-Ac*) 10 and ethyl hydroxytyrosyl ether (*HT-Et*). Data represents the means of eight determinations \pm SD*.

		Standard diet	Hypercholesterolemic diet				
Plasma nutrie	nts	С	Chol	HT	HT-Ac	HT-Et	
Glucose	(mg/dL)	140.50 ± 15.23^{a}	182.29 ± 18.17^{b}	143.25 ± 19.83^{a}	154.75 ± 23.36^{a}	160.00 ± 22.53^{ab}	
Triglycer	rides (mg/dL)	106.71 ± 21.69	100.29 ± 18.33	83.00 ± 29.50	90.50 ± 19.49	84.57 ± 13.90	
Free Fatty Acids (mM equivalents palmitic acid)		0.33 ± 0.07	0.30 ± 0.13	0.34 ± 0.07	0.31 ± 0.08	0.36 ± 0.07	
Creatinin	ne (mg/dL)	0.52 ± 0.02^{a}	0.58 ± 0.05 ^b	0.55 ± 0.02^{b}	0.53 ± 0.03^{a}	0.53 ± 0.03^{a}	
Hormones							
DI	Insulin (ng/mL)	972 ± 341^{a}	1560.2 ± 997.9^{b}	934.1 ± 390^{a}	608.1 ± 301.6^{a}	1121.3 ± 617.1^{ab}	
—— Plasma	Leptin (ng/mL)	2786 ± 908^{a}	4174± 1116 ^b	3609 ± 1022^{ab}	2970 ± 1150^{a}	3468.1 ± 1291^{ab}	
Adipose	Leptin (ng/µg pr)	682 ± 189	501 ± 178	503 ± 137	503 ± 148	671 ± 283	
tissue	Adiponectin(ng/µg pr)	726415 ± 139506	658737 ± 145887	593934 ± 67860	693282 ± 139463	653668 ± 66473	

12

13 * Mean values in a row with unlike superscripts are significantly different according to Kruskal-Wallis one-way analysis of variance and Mann-Whitney

14 U test (p < 0.05).

15

17 **Table 4.** Redox status and inflammatory biomarkers in plasma and adipose tissue of rats fed the control diet (*C*), the un-supplemented 18 cholesterol-rich diet (*Chol*) and the cholesterol-rich diet supplemented with hydroxytyrosol (*HT*), hydroxytyrosyl acetate (*HT-Ac*) and ethyl 19 hydroxytyrosyl ether (*HT-Et*). Data represents the mean of 8 determinations \pm SD*.

20

			Standard diet	Hypercholesterolemic diet			
			С	Chol	HT	HT-Ac	HT-Et
Antioxidant capacity	Serum Ol (mM T.ec		27.4 ± 1.8^{ab}	25.6 ± 2.3^{a}	28.4 ± 1.6^{b}	28.0 ± 1.2^{b}	26.2 ± 1.1^{a}
Lipid	ipid Serum (nmol/mL)		1.97 ± 0.75^{a}	3.54 ± 0.24^{b}	2.36 ± 0.23^{a}	2.19 ± 0.39^{a}	2.36 ± 0.30^{a}
oxidation	Liver (nmol/mg pr)		0.98 ± 0.33^{a}	3.33 ± 1.14^{b}	$2.52 \pm 0.92^{\rm bc}$	2.35 ± 0.81^{bc}	$2.11 \pm 0.53^{\circ}$
	Plasma	TNFα (ng/mL)	3.0 ± 0.7^{a}	4.2 ± 0.7^{b}	3.7 ± 0.8^{a}	2.7 ± 0.6^{a}	3.4 ± 0.7^{ab}
		IL-1 β (ng/mL)	11.6 ± 6.3	26.50 ± 21.5	13.8 ± 14.6	11.5 ± 7.1	8.0 ± 4.9
		IL-6 (ng/mL)	4.9 ± 4.4	3.66 ± 1.63	6.0 ± 3.3	5.7 ± 3.7	5.9 ± 2.4
Inflammatory		TNFα (ng/μg pr)	2.5 ± 0.6	2.2 ± 0.5	2.2 ± 0.5	2.0 ± 0.4	1.9 ± 0.3
mediators	Adipose tissue	IL-1 β (ng/ μ g pr)	3.9 ± 0.9^{a}	3.7 ± 0.8^{a}	3.8 ± 0.6^{a}	2.9 ± 0.4^{b}	3.1 ± 0.2^{b}
		IL-6 (ng/µg pr)	24.6 ± 7.0	23.7 ± 6.1	25.7 ± 7.4	20 ± 8	23.4 ± 6.5
		MCP-1 (ng/µg pr)	32.3 ± 7.4^{a}	$27.6 \pm 3.9^{\text{ a}}$	28.5 ± 3.9^{a}	26 ± 4^{b}	25.6± 3.4 ^b
		PAI-1(ng/µg pr)	87.6 ± 22.9	98.9 ± 32.9	92.4 ± 15.4	73.3 ± 18.0	81.5 ± 12.4

21

22 * Mean values in a row with unlike superscripts are significantly different according to Kruskal-Wallis one-way analysis of variance and Mann-Whitney

23 U test (p < 0.05).

